AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 MAY 6 - (NewsRx.com & NewsRx.net) -- Halozyme Therapeutics, Inc., (HZYM), a therapeutically driven biopharmaceutical company focused on the development and commercialization of recombinant human enzymes, announced it has signed a manufacturing agreement with Avid Bioservices, Inc., a wholly owned subsidiary of Peregrine Pharmaceuticals, Inc., (PPHM).
Avid will manufacture under current good manufacturing practices (cGMP) Halozyme's first recombinant human enzyme, which will be used in the development of Cumulase and Enhanze SC, Halozyme's first two product candidates. Cumulase and Enhanze SC will offer synthetic alternatives to impure slaughterhouse-derived enzymes currently used in the infertility and ophthalmology markets.
"We are pleased to contract with Avid for production of our first enzyme," said Jonathan Lim, MD, Halozyme's chairman and CEO. "Avid will handle the complete process from cell bank production to delivery of cGMP-manufactured bulk material. We are now well-positioned to rapidly advance our near-term products to the ...